Zika Vaccine Development: Current Status

Gregory A. Poland, Inna G. Ovsyannikova, Richard B. Kennedy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.

Original languageEnglish (US)
Pages (from-to)2572-2586
Number of pages15
JournalMayo Clinic proceedings
Volume94
Issue number12
DOIs
StatePublished - Dec 2019

Fingerprint

Vaccines
Licensure
Disease Outbreaks
Anxiety
Clinical Trials
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zika Vaccine Development : Current Status. / Poland, Gregory A.; Ovsyannikova, Inna G.; Kennedy, Richard B.

In: Mayo Clinic proceedings, Vol. 94, No. 12, 12.2019, p. 2572-2586.

Research output: Contribution to journalReview article

Poland, Gregory A. ; Ovsyannikova, Inna G. ; Kennedy, Richard B. / Zika Vaccine Development : Current Status. In: Mayo Clinic proceedings. 2019 ; Vol. 94, No. 12. pp. 2572-2586.
@article{0c389846b3e04f6882ebd0e083143893,
title = "Zika Vaccine Development: Current Status",
abstract = "Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.",
author = "Poland, {Gregory A.} and Ovsyannikova, {Inna G.} and Kennedy, {Richard B.}",
year = "2019",
month = "12",
doi = "10.1016/j.mayocp.2019.05.016",
language = "English (US)",
volume = "94",
pages = "2572--2586",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Zika Vaccine Development

T2 - Current Status

AU - Poland, Gregory A.

AU - Ovsyannikova, Inna G.

AU - Kennedy, Richard B.

PY - 2019/12

Y1 - 2019/12

N2 - Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.

AB - Zika virus outbreaks have been explosive and unpredictable and have led to significant adverse health effects—as well as considerable public anxiety. Significant scientific work has resulted in multiple candidate vaccines that are now undergoing further clinical development, with several vaccines now in phase 2 clinical trials. In this review, we survey current vaccine efforts, preclinical and clinical results, and ethical and other concerns that directly bear on vaccine development. It is clear that the world needs safe and effective vaccines to protect against Zika virus infection. Whether such vaccines can be developed through to licensure and public availability absent significant financial investment by countries, and other barriers discussed within this article, remains uncertain.

UR - http://www.scopus.com/inward/record.url?scp=85071855390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071855390&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.05.016

DO - 10.1016/j.mayocp.2019.05.016

M3 - Review article

C2 - 31806107

AN - SCOPUS:85071855390

VL - 94

SP - 2572

EP - 2586

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -